Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum bactericidal assay with human complement (hSBA). The vaccine consists of two factor H binding proteins (fHBPs) representing divergent subfamilies to ensure broad coverage. Although it is the surrogate of efficacy, an hSBA is not suitable for testing large numbers of strains in local laboratories. Previously, an association between the in vitro fHBP surface expression level and the susceptibility of NmB isolates to killing was observed. Therefore, a flow cytometric meningococcal antigen surface expression (MEASURE) assay was developed and validated by using an antibody that binds to all fHBP variants from both fHBP subfamilies and accurately quantitates the level of fHBP expressed on the cell surface of NmB isolates with mean fluorescence intensity as the readout. Two collections of invasive NmB isolates (n = 1,814, n = 109) were evaluated in the assay, with the smaller set also tested in hSBAs using individual and pooled human serum samples from young adults vaccinated with bivalent rLP2086. From these data, an analysis based on fHBP variant prevalence in the larger 1,814-isolate set showed that >91% of all meningococcal serogroup B isolates expressed sufficient levels of fHBP to be susceptible to bactericidal killing by vaccine-induced antibodies.IMPORTANCE Bivalent rLP2086 (Trumenba) vaccine, composed of two factor H binding proteins (fHBPs), was recently licensed for the prevention of N. meningitidis serogroup B (NmB) disease in individuals 10 to 25 years old in the United States. This study evaluated a large collection of NmB isolates from the United States and Europe by using a flow cytometric MEASURE assay to quantitate the surface expression of the vaccine antigen fHBP. We find that expression levels and the proportion of strains above the level associated with susceptibility in an hSBA are generally consistent across these geographic regions. Thus, the assay can be used to predict which NmB isolates are susceptible to killing in the hSBA and therefore is able to demonstrate an fHBP vaccine-induced bactericidal response. This work significantly advances our understanding of the potential for bivalent rLP2086 to provide broad coverage against diverse invasive-disease-causing NmB isolates.

Department of Bacteriology and Immunology Norwegian Institute of Public Health Oslo Norway

Department of Medicine University of California San Diego California USA

Institut Pasteur Invasive Bacterial Infections Unit Paris France

Institute for Hygiene and Microbiology University of Würzburg Würzburg Germany

Meningitis and Vaccine Preventable Diseases Branch Centers for Disease Control and Prevention Atlanta Georgia USA

National Institute of Public Health Prague Czech Republic

Pfizer Vaccine Research and Development Pearl River New York USA

Public Health England Manchester Royal Infirmary Manchester United Kingdom

Reference and Research Laboratory for Vaccine Preventable Bacterial Diseases Institute of Health Carlos 3 Majadahonda Spain

Comment In

mBio. 2018 May 15;9(3):e00713-18. doi: 10.1128/mBio.00713-18. PubMed

See more in PubMed

Stephens DS. 2007. Conquering the meningococcus. FEMS Microbiol Rev 31:3–14. doi:10.1111/j.1574-6976.2006.00051.x. PubMed DOI

Gabutti G, Stefanati A, Kuhdari P. 2015. Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage. J Prev Med Hyg 56:E116–E120. PubMed PMC

McNeil LK, Zagursky RJ, Lin SL, Murphy E, Zlotnick GW, Hoiseth SK, Jansen KU, Anderson AS. 2013. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev 77:234–252. doi:10.1128/MMBR.00056-12. PubMed DOI PMC

Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. 2001. Meningococcal disease. N Engl J Med 344:1378–1388. doi:10.1056/NEJM200105033441807. PubMed DOI

Finne J, Leinonen M, Mäkelä PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355–357. PubMed

Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J, Rosenqvist E. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27:B3–B12. doi:10.1016/j.vaccine.2009.04.071. PubMed DOI

Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, Berman SL, Lowenthal JP. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 126:514–521. doi:10.1093/infdis/126.5.514. PubMed DOI

Bernfield L, Fletcher LD, Howell A, Farley JE, Zagursky R, Knauf M, Zlotnick G. 2002. Identification of a novel vaccine candidate for group B Neisseria meningitidis, p 116 In Caugant DA, Wedege E (ed), Abstracts of the Thirteenth International Pathogenic Neisseria Conference. National Institute of Public Health, Oslo, Norway.

Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, Xie X, Zagursky R, Zhang Y, Zlotnick GW. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72:2088–2100. doi:10.1128/IAI.72.4.2088-2100.2004. PubMed DOI PMC

Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, Tang CM. 2006. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176:7566–7575. doi:10.4049/jimmunol.176.12.7566. PubMed DOI

Hoiseth SK, Murphy E, Andrew L, Vogel U, Frosch M, Hellenbrand W, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Mayer LW, Wang X, Macneil JR, York L, Tan CY, Jansen KU, Anderson AS. 2013. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J 32:1096–1101. doi:10.1097/INF.0b013e31829aa63b. PubMed DOI

Křížová P, Musílek M, Vacková Z, Kozáková J, Claus H, Vogel U, Medini D. 2014. Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic. Epidemiol Mikrobiol Imunol 63:103–106. PubMed

Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200:379–389. doi:10.1086/600141. PubMed DOI

Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R. 2013. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13:416–425. doi:10.1016/S1473-3099(13)70006-9. PubMed DOI

Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086–6093. doi:10.1016/j.vaccine.2010.06.083. PubMed DOI

. 2015. Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 57:5–6. PubMed

Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, Perez JL. 2013. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 31:1569–1575. doi:10.1016/j.vaccine.2013.01.021. PubMed DOI

Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, Jansen KU, Perez JL. 2013. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 32:364–371. doi:10.1097/INF.0b013e31827b0d24. PubMed DOI

Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL, 2001 Study Investigators . 2012. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12:597–607. doi:10.1016/S1473-3099(12)70087-7. PubMed DOI

Richmond PC, Nissen MD, Marshall HS, Lambert SB, Roberton D, Gruber WC, Jones TR, Arora A. 2012. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 30:6163–6174. doi:10.1016/j.vaccine.2012.07.065. PubMed DOI

Borrow R, Balmer P, Miller E. 2005. Meningococcal surrogates of protection—serum bactericidal antibody activity. Vaccine 23:2222–2227. doi:10.1016/j.vaccine.2005.01.051. PubMed DOI

Zlotnick GW, Jones TR, Liberator P, Hao L, Harris S, McNeil LK, Zhu D, Perez J, Eiden J, Jansen KU, Anderson AS. 2015. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B Disease. Hum Vaccin Immunother 11:5–13. doi:10.4161/hv.34293. PubMed DOI PMC

Harris SL, Donald RG, Hawkins JC, Tan C, O’Neill R, McNeil LK, Perez JL, Anderson AS, Jansen KU, Jones TR. 2017. Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J 36:216–223. doi:10.1097/INF.0000000000001399. PubMed DOI

Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS. 2017. Meningococcal serogroup B vaccines: estimating breadth of coverage. Hum Vaccin Immunother 13:255–265. doi:10.1080/21645515.2017.1264750. PubMed DOI PMC

Mascioni A, Bentley BE, Camarda R, Dilts DA, Fink P, Gusarova V, Hoiseth SK, Jacob J, Lin SL, Malakian K, McNeil LK, Mininni T, Moy F, Murphy E, Novikova E, Sigethy S, Wen Y, Zlotnick GW, Tsao DH. 2009. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem 284:8738–8746. doi:10.1074/jbc.M808831200. PubMed DOI PMC

Hoiseth SK, Murphy E, Andrew L, Lee KL, Ambrose K, Dilts D, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant D, Alvestad T, Mayer L, Wang X, Zlotnick GW, Jansen KU, Anderson AS. 2008. LP2086 and MLST distribution in epidemiologically relevant strains of serogroup B Neisseria meningitidis, p P137 In van Alphen L, van der Lay P, van den Dobbelsteen G (ed), Abstracts of the Sixteenth International Pathogenic Neisseria Conference. National Institute of Public Health, Rotterdam, The Netherlands.

Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE. 2010. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 50:184–191. doi:10.1086/649209. PubMed DOI

Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseth SK, Jansen KU, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LW. 2011. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 29:4739–4744. doi:10.1016/j.vaccine.2011.04.092. PubMed DOI

Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, Fleming D. 1999. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 281:1493–1497. doi:10.1001/jama.281.16.1493. PubMed DOI

Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177:501–510. doi:10.4049/jimmunol.177.1.501. PubMed DOI PMC

Litt DJ, Savino S, Beddek A, Comanducci M, Sandiford C, Stevens J, Levin M, Ison C, Pizza M, Rappuoli R, Kroll JS. 2004. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 190:1488–1497. doi:10.1086/424464. PubMed DOI

Ala’Aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, Murphy E, Giardina PC, Novikova EG, Dodge-Scully IL, Bayliss CD, Turner DP, Neal KR, Hoiseth SK, Jansen KU, Anderson AS. 2010. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 28:7667–7675. doi:10.1016/j.vaccine.2010.09.038. PubMed DOI

Jacobsson S, Mölling P, Olcén P. 2009. Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis. Vaccine 27:5755–5759. doi:10.1016/j.vaccine.2009.07.056. PubMed DOI

Biagini M, Spinsanti M, De Angelis G, Tomei S, Ferlenghi I, Scarselli M, Rigat F, Messuti N, Biolchi A, Muzzi A, Anderloni G, Brunelli B, Cartocci E, Buricchi F, Tani C, Stella M, Moschioni M, Del Tordello E, Colaprico A, Savino S, Giuliani MM, Delany I, Pizza M, Costantino P, Norais N, Rappuoli R, Masignani V. 2016. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci U S A 113:2714–2719. doi:10.1073/pnas.1521142113. PubMed DOI PMC

Frasch CE, Borrow R, Donnelly J. 2009. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27(Suppl 2):B112–B116. doi:10.1016/j.vaccine.2009.04.065. PubMed DOI

McIntosh ED, Bröker M, Wassil J, Welsch JA, Borrow R. 2015. Serum bactericidal antibody assays—the role of complement in infection and immunity. Vaccine 33:4414–4421. doi:10.1016/j.vaccine.2015.07.019. PubMed DOI

Kahler CM, Martin LE, Shih GC, Rahman MM, Carlson RW, Stephens DS. 1998. The (alpha2→8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun 66:5939–5947. PubMed PMC

Geoffroy MC, Floquet S, Métais A, Nassif X, Pelicic V. 2003. Large-scale analysis of the meningococcus genome by gene disruption: resistance to complement-mediated lysis. Genome Res 13:391–398. doi:10.1101/gr.664303. PubMed DOI PMC

Müller MG, Moe NE, Richards PQ, Moe GR. 2015. Resistance of Neisseria meningitidis to human serum depends on T and B cell stimulating protein B. Infect Immun 83:1257–1264. doi:10.1128/IAI.03134-14. PubMed DOI PMC

Taha MK, Hawkins JC, Liberator P, Deghmane AE, Andrew L, Hao L, Jones TR, McNeil LK, O’Neill RE, Perez JL, Jansen KU, Anderson AS. 2017. Bactericidal activity of serums from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine 35:1530–1537. doi:10.1016/j.vaccine.2017.01.066. PubMed DOI

McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, Mason K, Jiang HQ, Zhu D, Mininni TL, Zlotnick GW, Hoiseth SK, Jones TR, Pride MW, Jansen KU, Anderson AS. 2009. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27:3417–3421. doi:10.1016/j.vaccine.2009.01.075. PubMed DOI

Winder AF, Gent WL. 1971. Correction of light-scattering errors in spectrophotometric protein determinations. Biopolymers 10:1243–1251. doi:10.1002/bip.360100713. PubMed DOI

Peterson GL. 1977. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83:346–356. doi:10.1016/0003-2697(77)90043-4. PubMed DOI

Del Mar C, Greenbaum EA, Mayne L, Englander SW, Woods VL Jr. 2005. Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level. Proc Natl Acad Sci U S A 102:15477–15482. doi:10.1073/pnas.0507405102. PubMed DOI PMC

Englander JJ, Del Mar C, Li W, Englander SW, Kim JS, Stranz DD, Hamuro Y, Woods VL Jr. 2003. Protein structure change studied by hydrogen-deuterium exchange, functional labeling, and mass spectrometry. Proc Natl Acad Sci U S A 100:7057–7062. doi:10.1073/pnas.1232301100. PubMed DOI PMC

Hamuro Y, Zawadzki KM, Kim JS, Stranz DD, Taylor SS, Woods VL Jr. 2003. Dynamics of cAPK type IIbeta activation revealed by enhanced amide H/2H exchange mass spectrometry (DXMS). J Mol Biol 327:1065–1076. doi:10.1016/S0022-2836(03)00234-1. PubMed DOI

Pantazatos D, Kim JS, Klock HE, Stevens RC, Wilson IA, Lesley SA, Woods VL Jr. 2004. Rapid refinement of crystallographic protein construct definition employing enhanced hydrogen-deuterium exchange MS. Proc Natl Acad Sci U S A 101:751–756. doi:10.1073/pnas.0307204101. PubMed DOI PMC

Woods VL Jr, Hamuro Y. 2001. High resolution, high-throughput amide deuterium exchange-mass spectrometry (DXMS) determination of protein binding site structure and dynamics: utility in pharmaceutical design. J Cell Biochem Suppl 37:89–98. doi:10.1002/jcb.10069. PubMed DOI

Gribenko A, Mosyak L, Ghosh S, Parris K, Svenson K, Moran J, Chu L, Li S, Liu T, Woods VL Jr, Jansen KU, Green BA, Anderson AS, Matsuka YV. 2013. Three-dimensional structure and biophysical characterization of Staphylococcus aureus cell surface antigen-manganese transporter MntC. J Mol Biol 425:3429–3445. doi:10.1016/j.jmb.2013.06.033. PubMed DOI

Borrow R, Carlone GM. 2001. Serogroup B and C serum bactericidal assays. Methods Mol Med 66:289–304. doi:10.1385/1-59259-148-5:289. PubMed DOI

World Health Organization Department of Vaccines and Biologicals 1999. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A/C vaccines, Geneva, 8–9 March 1999. World Health Organization, Geneva, Switzerland: https://extranet.who.int/iris/restricted/bitstream/10665/66298/1/WHO_V%26B_99.19.pdf.

Genomic surveillance of invasive meningococcal disease in the Czech Republic, 2015-2017